| Title |
Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, May 2012
|
| DOI | 10.1007/s00259-012-2139-3 |
| Pubmed ID | |
| Authors |
Torsten Hinz, Hojjat Ahmadzadehfar, Anja Wierzbicki, Tobias Hoeller, Joerg Wenzel, Hans-J. Biersack, Thomas Bieber, Monika-H. Schmid-Wendtner |
| Abstract |
Sentinel lymph node biopsy (SLNB) is considered the most powerful prognostic indicator of survival in patients with cutaneous melanoma of intermediate thickness (1-4 mm). The use of SLNB in patients with melanoma with a tumour thickness >4.0 mm is still controversial. The purpose of the current study was to determine the prognostic value of SLNB in patients with thick cutaneous melanomas (tumour thickness >4.0 mm) in terms of progression-free survival (PFS) and overall survival (OS). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 24% |
| Student > Master | 4 | 24% |
| Student > Doctoral Student | 2 | 12% |
| Student > Postgraduate | 2 | 12% |
| Student > Ph. D. Student | 1 | 6% |
| Other | 3 | 18% |
| Unknown | 1 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 76% |
| Nursing and Health Professions | 1 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Unknown | 2 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2012.
All research outputs
#21,153,429
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#2,610
of 3,083 outputs
Outputs of similar age
#150,592
of 166,202 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#14
of 26 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,202 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.